Publications by authors named "Helen Berryman"
Clin Cancer Res
July 2021
Article Synopsis
- KA2507 is a newly developed and potent inhibitor of HDAC6, aimed at providing direct antitumor effects and enhancing the immune response against cancer.
- In preclinical studies, KA2507 showed effectiveness in treating melanoma and colorectal cancer, and in a phase I clinical trial, it was well-tolerated with no major toxicities observed.
- Some patients experienced prolonged disease stabilization, suggesting promising potential for KA2507 in future cancer treatments, possibly in combination with other immunotherapies.
